IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Clinical Trial Results: INB-200, a gamma-delta T cell therapy for glioblastoma multiforme, shows a median progression-free survival (mPFS) of 16.1 months in patients receiving multiple doses, significantly surpassing the standard-of-care mPFS of 6.9 months.
Safety Profile: The treatment is well-tolerated with no serious toxicities reported, and 40% of patients remain alive and progression-free for over two years, indicating promising long-term outcomes.
Trade with 70% Backtested Accuracy
Analyst Views on INAB
About INAB
About the author
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
IN8bio Secures $40.2 Million Financing to Advance INB-619
- Financing Amount: IN8bio has secured up to $40.2 million through a securities purchase agreement with institutional investors, with an initial $20.1 million aimed at advancing the IND application for INB-619, ensuring operational funding through the first half of 2027.
- Investor Participation: The financing is led by Coastlands Capital and includes participation from both new and existing investors such as Stonepine Capital Management and 683 Capital Partners, reflecting strong market confidence in IN8bio's innovative therapies.
- Equity Structure: The initial tranche involves the sale of 5,127,029 shares at $1.38 per share, along with pre-funded warrants, enhancing the company's capital flexibility and competitive positioning in the biopharmaceutical market.
- Clinical Research Plans: IN8bio intends to use the proceeds to fund IND enabling studies for INB-619, with expectations to engage with the FDA in 2026 and submit pivotal animal model data in 2027, thereby advancing the product's path to market.
IN8bio Secures $20.1 Million Financing to Advance INB-619
- Financing Agreement: IN8bio has entered into a securities purchase agreement with institutional investors for an initial $20.1 million, expected to extend its cash runway into the first half of 2027, ensuring operational stability during clinical development.
- Follow-on Financing Potential: The agreement includes an additional $20.1 million in milestone-driven financing, which will enhance the company's research capabilities in oncology and autoimmune diseases if preclinical data for INB-619 meets specified criteria.
- Equity Structure Optimization: The financing will issue 5,127,029 shares of common stock at $1.38 per share, along with pre-funded warrants for 9,452,677 shares, enhancing investor engagement and the company's capital flexibility.
- FDA Interaction Plan: IN8bio plans to engage with the FDA in 2026 for initial discussions, with an IND submission anticipated in 2027, aimed at accelerating the clinical development of INB-619 and improving market competitiveness.
IN8bio reveals private placement of up to $40.2M through at-the-market offering
Private Placement Agreement: IN8bio has entered into a definitive securities purchase agreement for a private placement aiming to raise approximately $40.2 million, with an initial tranche expected to generate about $20.1 million.
Share Sale Details: The company plans to sell 5.13 million shares at $1.38 each and pre-funded warrants for up to 9.45 million shares at the same price, with the initial closing anticipated around December 22, 2025.
Use of Proceeds: Funds raised will support IND-enabling studies for INB-619, advancement of glioblastoma programs INB-200 and INB-400, FDA interactions, and general corporate purposes.
Market Reaction: Following the announcement, IN8bio's shares experienced a 5% increase in premarket trading.
IN8bio (INAB) Q2 Loss Narrows 77%
Financial Performance: IN8bio reported a significantly reduced net loss in Q2 2025, with no revenue generated but a cash position of $13.2 million projected to last until June 2026, while research and development costs decreased due to strategic prioritization.
Clinical Progress: The company achieved promising results in its clinical trial for INB-200 in glioblastoma, showing a median progression-free survival of 16.1 months, which is more than double the standard treatment, alongside advancements in other therapies and manufacturing capabilities.
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
Market Overview: U.S. stock futures were flat following a positive close on Friday, with the S&P 500 surpassing 6,000 points, driven by strong job growth and a cooling of tensions between Elon Musk and President Trump. Investors are awaiting upcoming inflation data and the Federal Reserve's interest rate decision.
Sector Performance: All sectors of the S&P 500 closed positively on Friday, led by consumer discretionary, energy, and communication services, although some individual stocks like ABM Industries and DocuSign saw significant declines after disappointing earnings reports.
IN8bio Unveils Private Placement Funding Initiative
Securities Purchase Agreement: IN8bio, Inc. has finalized a securities purchase agreement to raise approximately $40.2 million through a private placement involving new and existing institutional investors, as well as company directors and officers.
Funding Allocation: The funds from the initial closing, estimated at $20.1 million, will support operations until mid-2027 and facilitate IND-enabling studies for INB-619, along with regulatory efforts for glioblastoma programs INB-200 and INB-400.
Current Stock Performance: INAB's stock is currently trading at $1.36, reflecting a decrease of $0.02 or 1.45 percent on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
IN8bio Secures $40.2 Million Financing to Advance INB-619
- Financing Amount: IN8bio has secured up to $40.2 million through a securities purchase agreement with institutional investors, with an initial $20.1 million aimed at advancing the IND application for INB-619, ensuring operational funding through the first half of 2027.
- Investor Participation: The financing is led by Coastlands Capital and includes participation from both new and existing investors such as Stonepine Capital Management and 683 Capital Partners, reflecting strong market confidence in IN8bio's innovative therapies.
- Equity Structure: The initial tranche involves the sale of 5,127,029 shares at $1.38 per share, along with pre-funded warrants, enhancing the company's capital flexibility and competitive positioning in the biopharmaceutical market.
- Clinical Research Plans: IN8bio intends to use the proceeds to fund IND enabling studies for INB-619, with expectations to engage with the FDA in 2026 and submit pivotal animal model data in 2027, thereby advancing the product's path to market.
IN8bio Secures $20.1 Million Financing to Advance INB-619
- Financing Agreement: IN8bio has entered into a securities purchase agreement with institutional investors for an initial $20.1 million, expected to extend its cash runway into the first half of 2027, ensuring operational stability during clinical development.
- Follow-on Financing Potential: The agreement includes an additional $20.1 million in milestone-driven financing, which will enhance the company's research capabilities in oncology and autoimmune diseases if preclinical data for INB-619 meets specified criteria.
- Equity Structure Optimization: The financing will issue 5,127,029 shares of common stock at $1.38 per share, along with pre-funded warrants for 9,452,677 shares, enhancing investor engagement and the company's capital flexibility.
- FDA Interaction Plan: IN8bio plans to engage with the FDA in 2026 for initial discussions, with an IND submission anticipated in 2027, aimed at accelerating the clinical development of INB-619 and improving market competitiveness.
IN8bio reveals private placement of up to $40.2M through at-the-market offering
Private Placement Agreement: IN8bio has entered into a definitive securities purchase agreement for a private placement aiming to raise approximately $40.2 million, with an initial tranche expected to generate about $20.1 million.
Share Sale Details: The company plans to sell 5.13 million shares at $1.38 each and pre-funded warrants for up to 9.45 million shares at the same price, with the initial closing anticipated around December 22, 2025.
Use of Proceeds: Funds raised will support IND-enabling studies for INB-619, advancement of glioblastoma programs INB-200 and INB-400, FDA interactions, and general corporate purposes.
Market Reaction: Following the announcement, IN8bio's shares experienced a 5% increase in premarket trading.
IN8bio (INAB) Q2 Loss Narrows 77%
Financial Performance: IN8bio reported a significantly reduced net loss in Q2 2025, with no revenue generated but a cash position of $13.2 million projected to last until June 2026, while research and development costs decreased due to strategic prioritization.
Clinical Progress: The company achieved promising results in its clinical trial for INB-200 in glioblastoma, showing a median progression-free survival of 16.1 months, which is more than double the standard treatment, alongside advancements in other therapies and manufacturing capabilities.
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
Market Overview: U.S. stock futures were flat following a positive close on Friday, with the S&P 500 surpassing 6,000 points, driven by strong job growth and a cooling of tensions between Elon Musk and President Trump. Investors are awaiting upcoming inflation data and the Federal Reserve's interest rate decision.
Sector Performance: All sectors of the S&P 500 closed positively on Friday, led by consumer discretionary, energy, and communication services, although some individual stocks like ABM Industries and DocuSign saw significant declines after disappointing earnings reports.
